2. Academic Validation
  3. Macrophage-Biomimetic Nanoparticles Ameliorate Ulcerative Colitis through Reducing Inflammatory Factors Expression

Macrophage-Biomimetic Nanoparticles Ameliorate Ulcerative Colitis through Reducing Inflammatory Factors Expression

  • J Innate Immun. 2022;14(4):380-392. doi: 10.1159/000519363.
Zhengshuo Li 1 2 3,  Xiaoyue Zhang 2 3,  Can Liu 2 3,  Qiu Peng 2 3,  Yangge Wu 2 3,  Yuqing Wen 2 3,  Run Zheng 2 3,  Qun Yan 4,  Jian Ma 1 2 3
Affiliations

Affiliations

  • 1 Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
  • 2 Cancer Research Institute and School of Basic Medical Science, Central South University, Changsha, China.
  • 3 Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Changsha, China.
  • 4 Department of Clinical Laboratory, Hematology, Xiangya Hospital, Central South University, Changsha, China.
PMID: 34724662 DOI: 10.1159/000519363
Abstract

Background and aims: Inflammatory mediator S100A9 is dramatically elevated in ulcerative colitis and correlates with disease severity. S100A9 is a potential molecule to target for the treatment of colitis, but to date, there is no effective targeting method. The aim of this study was to develop a safe and effective nano-delivery system targeting S100A9 and to evaluate its therapeutic efficacy in ulcerative colitis mouse model.

Methods: We designed an oral nano-delivery system using poly (lactic acid-glycolic acid) (PLGA)-loaded S100A9 inhibitor tasquinimod to synthesize PLGA-TAS nanoparticles. TLR4-overexpressing macrophage membranes (MMs) were used to wrap the nanoparticles to make MM-PLGA-TAS, which allowed the nanoparticles to acquire the ability to specifically enrich the colitis region.

Results: MM-PLGA-TAS was endocytosed by inflammatory phenotype RAW264.7 cells in vitro and can efficiently enrich in inflamed mouse colitis tissue in vivo. A chemically induced ulcerative colitis mouse model was used to evaluate the therapeutic effect of oral MM-PLGA-TAS. MM-PLGA-TAS significantly alleviated the symptoms of ulcerative colitis, and mechanically, MM-PLGA-TAS achieved immunomodulatory and suppressive effects by reducing S100a9 and other cytokines in the colitis region.

Conclusion: We describe a convenient, orally targeted colitis drug delivery system that cures the disease in ulcerative colitis mice. This system substantially increases drug accumulation in inflamed colonic tissue, reduces the risk of systemic exposure, and is a promising therapeutic approach against ulcerative colitis.

Keywords

Biomimetic nanoparticles; Drug delivery system; S100A9 inhibitor; Ulcerative colitis.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-10528
    99.94%, S100A9 Inhibitor